CompletedPhase 2

Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus

United States17 participantsStarted 2018-02-19

Plain-language summary

This study will evaluate the effectiveness and safety of an investigational drug, IV ganaxolone, as adjunctive therapy to standard of care to treat subjects with status epilepticus.

Who can participate

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects 12 years of age and older * Clinical and/or electrographic seizures Exclusion Criteria: * Life expectancy of less than 24 hours * Anoxic brain injury as primary cause of SE * Recent (\<24 hour) traumatic brain injury as the primary cause of SE * Administered anesthesia for the treatment of SE

What they're measuring

Number of Participants Who Did Not Require an IV Anesthetic Drug for SE Treatment

Timeframe: 24 hours post study drug initiation

Trial details

NCT IDNCT03350035

SponsorMarinus Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-09-18

Results submitted2022-09-28

View on ClinicalTrials.gov More Status Epilepticus trials